VITA 34 AG Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 5/8/2026)
| Balance Sheet | Total Assets | 168,259,000.00 | ROE | 4.23 % |
| Balance Sheet | Total Equity | 7,117,000.00 | ROA | -3.75 % |
| Cashflow | Capital Expenditures | -4,127,000.00 | P/FCF | -206.52 |
| Cashflow | Free Cash Flow | -249,000.00 | – | – |
| Cashflow | Operating Cash Flow | 3,878,000.00 | P/CF | 13.26 |
| Income | Earnings per Share (diluted) | -0.36 | Div. Yield | – |
| Income | Net Income | -6,303,000.00 | P/E | -8.19 |
| Income | Shares Outstanding | 17,431,800.00 | P/B | 7.23 |
| Income | Total Revenue | 88,173,000.00 | P/S | 0.58 |
Ratios calculated on: 10/14/2026
Company Description
VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous immune cells; and CAR-T. In addition, the company manufactures advanced therapy medicinal products based on mesenchymal stem cells for experimental treatment by specialized medical institutions; preserves stem cells from perinatal tissue and adult body fat; and engages in the contract manufacturing of pharmaceutical intermediates. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.vita34.de
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more